Overall survival in BRCA-associated ovarian cancer: Case-control study of an Italian series

European Journal of Gynaecological Oncology

Volumn 31, Issue 6, 2010, Pages 658-661

  Artioli, G ^a   Borgato, L ^a   Cappetta, A ^a   Wabersich, J ^a   Mocellin, S ^a   Dalla Palma, M ^a   Nicoletto, O ^a  

^a NONE

Author keywords

BRCA1; BRCA2; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; CANCER GRADING; CASE CONTROL STUDY; CLINICAL FEATURE; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GERM LINE; HIGH RISK PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL;

ADULT; AGE OF ONSET; AGED; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; ITALY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 78751523934     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Parkin D.M., Bray F., Ferlay J., Pisani P.: "Global cancer statistics". CA Cancer J. Clin., 2005, 55, 74.
2. Bristow R.E., Montz F.S., Lagasse L.D., Leuchter R.S., Karian B.Y.: "Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer". Gynecol. Oncol, 1999, 72, 278
3. Risch H.A., McLaughlin J.R., Cole D.E.C., Rosen B., Bradley L., Kwan E. et al.: "Prevalence and penetrance of germline BRCAl and BRCA2 mutations in a population series of 649 women with ovarian cancer". Am. J. Hum. Genet., 2001, 68, 700.
4. King M.C., Marks J.H., Mandeli J.B., New York Breast Cancer Study Group: "Breast and ovarian cancer risk due to inherited mutations in BRCAl and BRCA2". Science, 2003,302, 643
5. Foulkes W.D.: "BRCAl and BRCA2: chemosensitivity, treatment outcomes and prognosis". Fam. Cancer, 2006, 5, 135.
6. Pharoah D., Easton D.F., Stockton D.L., Gayther S., Ponder B.A.: "Survival in familial BRCA 1 associated and BRCA2 associated epithelial ovarian cancer". Cancer Res., 1999, 56, 868.
7. Aida H., Takakuwa K., Nagata H., Tsuneki I., Takano M., Tsuji S. et al.: "Clinical features of ovarian cancer in Japanese women with germline mutations of BRCAl". Clin. Cancer Res., 1998, 4, 235.
8. Boyd J., Sonoda Y., Federici M., Bogomolniy F., Rhei E., Maresco D.L. et al.: "Clinicopathological features of BRCAl linked and sporadic ovarian cancer". JAMA, 2000, 283, 2260.
9. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., Karian B.Y.: "Improved survival in women with BRCA associated ovarian cancer". Cancer, 2003, 97, 2187.
10. Johannsson O.T., Ranstam J., Borg A., Olsson H.: "Survival of BRCAl breast and ovarian cancer patients: a population based study from Southern Swden". J. Clin. Oncol, 1998, 16, 397.
11. Ben David B.Y., Chetrit A., Hirsh-Yechezkel G., Friedman E., Beck B.D., Beller V. et al.: "Effect of BRCA mutations on the length of survival in epithelial ovarian tumors". J. Clin. Oncol, 2002, 20, 463.
12. Zweemer R.P., Verheijen R.H., Coebergh J.W., Jacobs I.J., van Diest P.J., Gille J.J. et al.: "Survival analysis in familial ovarian cancer, a case control study". Eur. J. Obstet. Gynecol. Reprod. Biol, 2001, 95,219.
13. Ramus S.J., Fishman, Pharoah P.D.,Yarkoni S., Altaras M., Ponder B.A.: "Ovarian cancer survival in Ashkenazi Jewish patients with BRCAl and BRCA2 mutations". EJSO, 2001, 27, 278.
14. Buller R.E., Shahin M.S., Geisler J.P., Zog C.M., Deyoung B.R., Davis C.S. et al.: "Failure of BRCAl dysfunction to alter ovarian cancer survival". Clin. Cancer Res., 2002, 8, 1196.
15. Kringen P., Wang Y., Dumeaux V., Nesland J.M., Kristensen G., Borresen-Dale A.L. et al.: "TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCAl founder mutations; relation to age at diagnosis and survival". BMC Cancer, 2005, 5, 134.
16. Pal T., Permuth-Wey J., Kapoor R., Cantor A., Sutphen R.: "Improved survival in BRCA2 carriers with ovarian cancer". Fam. Cancer, 2007,6, 113.
17. Chetrit A., Hirsh-Yechezkel C., Ben-David Y, Lubin E, Friedman E., Sadetzki S.: "Effect of BRCAI/2 mutations on long-term survival of invasive ovarian cancer". J. Clin. Oncol, 2008,26, 20.
18. Venkitaraman A.R.: "Cancer susceptibility and the functions of BRCAl and BRCA2". Cell, 2002, 25, 171.
19. Rhei E., Bogomolniy R, Federici M.G., Maresco D.L., Offit K., Robson M.E. et al.: "Molecular genetic characterization of BRCAl and BRCA 2 linked hereditary ovarian cancers". Cancer Res., 1998,55,3193.
20. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., Hatkin D.P.: "The role of BRCAl in the cellular response to chemotherapy". JNCI, 2004, 96, 1659.
21. Taniguci T., Tischkowitz M., Ameziane N., Hodgson S.V., Mathew G.C., Joenje H. et al.: "Disruption of the Fanconi anemia-BRCA pathway in cisplatin sensitive ovarian tumors". Nat. Med., 2003,9, 568.
22. Olopade O.I., Artioli G.: "Efficacy of risk-reducing salpingooophorectomy in women with BRCA-I and BRCA-2 mutations". Breast J., 2004 (suppl. 1), S5.